Table 2

Multivariable analysis of drug discontinuation.

HR95% CIP values
TCZ mono vs TNFi combo0.780.70 to 0.86<0.001
TNFi mono vs TNFi combo1.151.06 to 1.23<0.001
TCZ mono vs TCZ combo0.960.86 to 1.080.53
TCZ mono vs TNFi mono0.650.58 to 0.74<0.001
TCZ combo vs TNFi combo0.700.65 to 0.76<0.001
TCZ combo vs TNFi mono0.650.59 to 0.72<0.001
  • Adjusted by age, gender, disease duration, seropositivity, number of previous biologic disease-modifying antirheumatic drugs, glucocorticoids at baseline, Disease Activity Score 28 at baseline, Clinical Disease Activity Index at baseline, Health Assessment Questionnaire at baseline.

  • combo, combination therapy; mono, monotherapy; TCZ, tocilizumab; TNFi, tumour necrosis factor inhibitor.